<img height="1" width="1" style="display:none" alt="" src="https://www.facebook.com/tr?id=367542720414923&amp;ev=PageView&amp;noscript=1">

    Not Found

  • 8:00 AM

    REGISTRATION & LIGHT BREAKFAST

  • MORNING SESSIONS

  • 9:00 AM
    Anemone Kasasbeh (1)

    Chairperson Opening Remarks

    Anemone Kasasbeh,PhD, - Manager of Data Science and Clinical AI - Ascension

    Arrow
  • 9:10 AM
    Nirav Parikh, Head of Enterprise Data and AI  - Mass General Brigham Healthcare

    OPENING KEYNOTE: Building the Foundations for Agentic AI in Healthcare: Data, Context and Governance

    Nirav Parikh - Head of Enterprise Data and AI - Mass General Brigham Healthcare

    Arrow
  • 9:40 AM
    Screenshot 2026-10-21 at 9.27.58 AM

    Spotlight session by WalkMe: See Healthcare AI Go From Ignored to Indispensable in 10 Minutes

    Jon Brockway - Vice President, Solution Advisory – Americas - WalkMe Inc.

    Arrow
    • See errors caught at the point of entry, before they become a financial loss or risk
    • Learn how a new hire can complete a complex task correctly on the first try
    • Discover AI guidance that prompts the user inside a live application, at the moment of need
    • Understand the analytics leaders use to spot where AI adoption stalls.
  • 10:00 AM
    Rafael Areses-1

    Presentation: Why AI Demos Don’t Deliver Healthcare Innovation

    Rafael Areses, - Medical Doctor MD DDS OS, Senior Advisor, Author and AI Tech Speaker -

    Arrow
    • Beyond the demo: what separates technical success from measurable patient value?
    • Scale, improve or stop: designing AI pilots around clear decisions, budgets and accountability.
    • Who pays, who leads, who owns the risk? Tackling the unanswered questions that stall adoption.
    • Making AI work in clinical practice: aligning safety, sustainable funding and everyday workflows.
  • 10:30 AM

    Coffee and Networking Break in the Exhibition Area

  • 11:00 AM
    Panel Discussion-3

    Panel: Beyond the Chatbot: Scaling Conversational AI Across the Patient Journey

    Arrow
    • Integrating patient-reported outcomes, wearable data and remote monitoring into clinical workflows to build a more complete picture of patients between visits.
    • Using conversational AI, voice and SMS to collect patient updates, identify emerging concerns and support more personalised follow-ups.
    • Turning continuous patient data into actionable insights, with clear escalation pathways that help care teams distinguish meaningful clinical signals from noise.
    • Measuring whether AI-enabled patient engagement improves care navigation, early intervention and patient outcomes without increasing clinicians’ workload.

    Moderator:  Joy H. Lewis, DO, PhD,Professor of Internal Medicine and Public Health; Founder, National Center for Community Health Research; Medical Advisor, Allimb -A .T. Still University

    Erlyn Macarayan, PhD, Vice President of Data Science - PatientsLikeMe (Fuze Health)

    Manasi Ghogare, Senior Technical Product Manager, Digital Health – Takeda

  • 11:30am

    Fireside chat: From Scientific Promise to Commercial Product — Scaling AI Across the Product Lifecycle

    Arrow

    • Translating experimental AI capability into a validated, supported business offering

    • Aligning medical, regulatory, market access, commercial, and technology teams

    • Building a credible value proposition for providers, payers, researchers, and patients

    • Avoiding the transition gap between successful prototype and sustainable product

    Moderator: Joy H. Lewis, DO, PhD,Professor of Internal Medicine and Public Health; Founder, National Center for Community Health Research; Medical Advisor, Allimb -A .T. Still University 

    Cheng Yang, Digital Diagnostics Lead - Tekeda  

  • 12:00 AM

    PANEL: Partner, Build or Buy? Who Owns the AI and the Risk?

    Arrow
    • Deciding where to build proprietary AI capabilities, buy external solutions or partner for greater impact.
    • Evaluating technology providers, startups and research partners beyond technical promises and vendor hype.
    • Defining ownership, accountability and liability when AI systems influence critical decisions.
    • Structuring partnerships that protect intellectual property, enable data sharing and distribute risk while delivering measurable outcomes.

    Moderator: Rafael Areses, Medical Doctor MD DDS OS, Senior Advisor, Author and AI Tech Speaker

    Dalbir Bains, President & CEO - Galaxy Pharmaceuticals LLC

    Amir Tahmasebi, Head of AI Algorithms and Infrastructure – BD

    Jacey Zhang, Associate Director - AI & Digital Enablement Lead -Takeda

  • 12:30 PM

    Lunch and Networking in the Exhibit Hall

  • 1:30 PM
    Fireside Chat

    Fireside chat: Trust at Scale — What Patients, Professionals & Regulators Need to See

    Arrow

    • Moving beyond broad principles to visible evidence of safety, fairness, and accountability

    • Communicating how AI is used without overwhelming patients or frontline professionals

    • Responding transparently when models underperform or produce unintended outcomes

    • Making trust a measurable operational asset rather than a communications exercise

    Marissa Seligman, PharmD, VP, Clinical Data Optimization, Real-World Data Solutions - Optum Life Sciences

    Alyce Kuklinski, NP, RN ,VP, Client Solutions, Real World Data Solutions - Optum Life Sciences

  • 2:00 PM
    President & CEO - Galaxy Pharmaceuticals LLC

    Presentation: Why AI Stalls at 1% in Pharma, and How We Got to 20%

    Dalbir Bains - President & CEO - Galaxy Pharmaceuticals LLC

    Arrow

    Most pharma companies get AI to about 1% of their work and stall there, in pilots that never reach production because no one can show an inspector who checked what. Dalbir Bains, CEO of Galaxy Pharmaceuticals, a 503B outsourcing facility in Albany, New York, shows how Galaxy moved AI to 20% of its work inside a cGMP operation without a single compliance shortcut, with a live demo: a deviation goes from logged to a drafted investigation and CAPA, and a person reviews and signs at every step.

    • Why AI stalls at 1%: the blocker in pharma isn't the model. It's data that isn't connected and work that no one can trace.
    • AI does the work, people keep the signatures: every AI output is reviewed and signed by a named owner, which is what makes it inspection-ready.
    • Agents follow the SOPs: each agent runs a procedure step by step and has a human owner, so it holds the process accountable instead of bypassing it.
    • Measure tools, not pilots: connect every system first, then judge progress by the tools in people's hands.
  • 2:30 PM

    Closing Remarks

    Arrow
  • 2:50 PM

    End of the Summit

AI in Healthcare & Pharma Summit

AI in Healthcare & Pharma Summit

November 17-18, 2026

Register Interest